查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138312

全球癌症干细胞市场-2022-2029

Global Cancer Stem Cells Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

影响全球癌症干细胞市场的因素正在增加对干细胞研究和癌症的资助，以及不断增长的抗 CSCs 疗法。

用于干细胞研究和癌症研究的资金不断增加预计将推动市场增长。

美国国家癌症研究所 (NCI) 是世界上最大的癌症研究资助者。根据国会的规定，研究所的年度预算约为 62.5 亿美元。这些赠款有助于建立基础设施，以继续在 NCI 和世界各地的癌症中心、医院、社区诊所和大学进行癌症研究。

美国国家癌症研究所 (NCI) 设有多个部门和中心，负责开展研究或管理研究项目。 NCI 2020 财年的资金为 64 亿美元（包括 1.95 亿美元的 CURES 法案资金），比上一年增加 5.24 亿美元，即 9.2%。美国癌症研究协会 (AACR) 是世界上第一个也是最大的癌症研究组织，致力于让癌症成为过去。此外，作为美国国立卫生研究院以外干细胞研究的最大资金来源，CIRM 赞助创新研究计划，重点是快速将药物提供给医疗需求未得到满足的患者。这包括基础研究，例如探索性研究和转化研究，以及临床试验。因此，增加对癌症研究和干细胞的资助预计将在预测期内推动市场增长。

预计在预测期内，高成本将阻碍市场增长。

细胞疗法和其他再生医学作为对现代医学的潜在变革性贡献而受到广泛关注，但它们的成本很高。人口增长和老龄化已经给公共卫生支出带来压力，这给许多私人保险公司的预算带来压力。但付款人的现金流管理系统却不是这种情况。

行业分析

癌症干细胞市场根据各种行业因素（包括搬运工五力、供应炼和价格分析）对市场进行了深入分析。

COVID-19 影响分析

预计干细胞疗法用于 COVID-19 将对市场增长产生积极影响。例如，抗病毒药、抗疟药和抗炎药是目前正在研究治疗 COVID-19 疾病的疗法之一。这些治疗可以帮助患者康復并延长寿命，但它们不能完全逆转由疾病引起的肺损伤。干细胞疗法以及最近由干细胞释放的细胞外囊泡 (EV) 已成为一种新型且有前景的疗法，可在修復 COVID-19 肺损伤的同时减少炎症。

据推测，干细胞通过其 EV 发挥治疗作用，例如免疫调节、抗氧化和恢復作用，并且可能单独或与其他治疗药物联合用于 COVID-19 患者。有一种性质。目前，有 17 项临床试验研究 MSCs 作为 COVID-19 的治疗方法，其中大部分是静脉注射，只有一项试验测试吸入 MSC 衍生的外泌体。因此，干细胞治疗的需求有望推动市场增长。

全球癌症干细胞市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 增加对干细胞研究和癌症研究的资助有望推动市场增长。
    • 限制因素
      • 预计在预测期内，高成本将阻碍市场增长。
    • 机会
    • 影响分析

第5章行业分析

  • 波特的五种力量
  • 未满足的需求
  • 供应链
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 发布前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按癌症类型

  • 血癌
  • 乳腺癌
  • 结肠癌
  • 肺癌
  • 肝癌
  • 脑肿瘤
  • 其他

第 8 章作用机制

  • 使用干细胞治疗癌症
    • 自体干细胞移植
    • 异基因干细胞移植
  • 针对癌症干细胞 (CSC) 的疗法
    • 通过抗癌干细胞药物
      • 通路抑製剂
      • WNT 信号通路
      • Hedgehog 信号通路
      • Notch 信号通路
      • 其他
      • 表面标记底座
      • 免疫逃避/肿瘤微环境靶向治疗
      • 使用纳米粒子进行治疗
      • 其他
    • 按产品
      • 细胞培养
      • 细胞分离
      • 细胞分析
      • 分子生物学分析
      • 其他

第 9 章，最终用户

  • 癌症治疗设施
  • 医院
  • 研究所
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • 默克公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Bionomics.
  • AbbVie, Inc.
  • Stemline Therapeutics, Inc
  • LONZA
  • PromoCell GmbH
  • Miltenyi Biotec
  • STEMCELL Technologies Inc
  • BIOTIME, Inc

第13章 全球癌症干细胞市场-DataM

简介目录
Product Code: DMPH372

Market Overview

Cancer stem cells market size is estimated to reach USD million by 2029, growing at a CAGR of 6.7 % during the forecast period (2022-2029).

Cancer stem cells are uncommon immortal cells seen in tumors that give rise to a diverse range of cell types that make up the tumor. These cells have been found in a number of human malignancies and may be employed as cancer therapeutic targets.

Market Dynamics

The factors influencing the global cancer stem cells market are increasing funding for stem cell research and cancer and the growing anti-CSCs therapeutics pipeline.

Increasing funding for stem cell research and cancer research is expected to drive market growth.

The National Cancer Institute (NCI) is the world's largest funder of cancer research. The institute's annual budget is roughly $6.25 billion, as established by Congress. These grants help finance the infrastructure that allows cancer research to continue at NCI and other cancer centers, hospitals, community clinics, and colleges worldwide.

The National Cancer Institute (NCI) contains a variety of divisions and centers that perform research or manage research projects. The NCI had $6.4 billion in funds in FY 2020 (including $195 million in CURES Act funding), up 9.2 percent or $524 million from the previous fiscal year. The American Association for Cancer Research (AACR) is the world's first and biggest cancer research organization dedicated to making cancer a thing of the past. Moreover, CIRM sponsors innovative research initiatives focused on expediting medicines to patients with unmet medical needs as the largest source of financing for stem cell research outside the National Institutes of Health. This includes everything from basic research, such as discovery and translational research, to clinical trials. Hence, the increased funding for cancer research and stem cells is expected to drive market growth in the forecast period.

High costs are expected to hamper the market's growth in the forecast period.

Cellular treatments and other regenerative medicines are gaining traction as potentially transformational contributions to modern medicine but at a hefty price tag. Growing and aging populations are already straining public healthcare costs, and many commercial insurers' budgets are also being pressured. Most payers' cash-flow management systems are not.

Industry Analysis

The cancer stem cells market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.

COVID-19 Impact Analysis

The use of stem cell therapies for COVID-19 is expected to positively impact market growth. For instance, antiviral, antimalarial, and anti-inflammatory drugs are among the treatments now being studied for the treatment of COVID-19 disease. While these treatments can help patients recover and live longer, they do not completely restore the lung damage caused by this disease. Stem cell therapies, and more recently, their released extracellular vesicles (EVs), are emerging as novel and promising treatments that may reduce inflammation while also repairing COVID-19-induced lung damage.

Stem cells presumably exert their immunomodulatory, anti-oxidant, and reparative therapeutic actions through their EVs, which could be useful in people with COVID-19, either alone or combined with other treatment drugs. There are currently 17 clinical trials examining MSCs for the treatment of COVID-19, most of which are administered intravenously, with just one experiment testing MSC-derived exosomes by inhalation. Hence, the demand for stem cell therapies is expected to drive market growth.

Segment Analysis

Stem Cell-based Cancer Therapy segment is expected to hold the largest market share in cancer stem cells market.

The stem cell-based cancer therapy segment accounted for the largest market share in 2021. Stem cell-based cancer therapy is further segmented into autologous SC transplants and allogeneic transplants. Stem cell transplants are treatments that help people who have had their blood-forming stem cells destroyed by heavy doses of chemotherapy or radiation therapy used to treat certain cancers. Blood-forming stem cells are crucial because they differentiate into many types of blood cells. An autologous stem cell transplant replaces diseased or damaged bone marrow with healthy blood stem cells from the recipient's body. An autologous bone marrow transplant is similar to an autologous stem cell transplant. When compared to stem cells from a donor, using cells from one's own body during a stem cell transplant has some advantages. If the body produces enough healthy bone marrow cells, an autologous stem cell transplant may be an option.

These cells can be collected, frozen, and used later. People who require severe doses of chemotherapy and radiation to cure their conditions frequently have autologous stem cell transplants. The bone marrow is likely to be damaged due to these treatments. The damaged bone marrow can be replaced with an autologous stem cell transplant. In contrast, an allogeneic stem cell transplant replaces bone marrow that isn't producing enough healthy blood cells with healthy blood stem cells from a donor. An allogeneic bone marrow transplant is similar to an allogeneic stem cell transplant.

Geographical Analysis

North American region holds the largest market share in the global cancer stem cells market

The growing prevalence of cancer and increasing R&D is expected to drive the market in this region. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, although stem cell research is allowed in the United States, it is subject to funding and usage restrictions. Blood cell-forming adult stem cells found in the bone marrow are currently the only stem cells employed to treat illness. Furthermore, many companies in this region are key players, such as Thermo Fisher Scientific, AbbVie, Inc., Stemline Therapeutics, Inc, STEMCELL Technologies, Inc, and others. In addition, Gamida-Cell Ltd., a U.S.-based next-generation stem cell therapy research and development business, will begin rolling out Biologics License Application (BLA) submissions for omidubicel on January 31, 2022. Omidubicel is a bone marrow stem cell transplant clinically developed for patients with blood malignancies. Gamida-Cell Ltd. stated that the rolling submission was approved following good comments from the type B meeting with the FDA.

Competitive Landscape

Major key players in the cancer stem cells market are Merck KGaA, Thermo Fisher Scientific, Inc., Bionomics, AbbVie, Inc., Stemline Therapeutics, Inc, LONZA, PromoCell GmbH, Miltenyi Biotec, STEMCELL Technologies Inc., BIOTIME, Inc.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

Thermo Fisher Scientific provides optimized solutions for cancer stem cell research-from identification and culturing to genomic and functional analysis.

  • Attune NxT Flow Cytometer
  • Cell Health Assays
  • TaqMan Protein Expression Assay

The global cancer stem cells market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing funding for stem cell research and cancer research is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs are expected to hamper the market's growth in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type Segment
  • 7.2. Blood Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Liver Cancer
  • 7.7. Brain Cancer
  • 7.8. Others

8. By Mode of Action

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 8.1.2. Market Attractiveness Index, By Mode of Action Segment
  • 8.2. Stem Cell-based Cancer Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Autologous Stem Cell Transplant
    • 8.2.4. Allogeneic Stem Cell Transplant
  • 8.3. Targeted Cancerous Stem Cells (CSCs)
    • 8.3.1. By Anti-Cancer Stem Cell Therapeutics
      • 8.3.1.1. Pathway Inhibitors
      • 8.3.1.1.1. WNT Signaling Pathway
      • 8.3.1.1.2. Hedgehog Signaling Pathway
      • 8.3.1.1.3. Notch Signaling Pathway
      • 8.3.1.1.4. Others
      • 8.3.1.2. Surface Marker-based
      • 8.3.1.3. Immuno-evasion & Targeting Tumor Microenvironment
      • 8.3.1.4. Nanoparticle-based Therapies
      • 8.3.1.5. Others
    • 8.3.2. By Products
      • 8.3.2.1. Cell Culturing
      • 8.3.2.2. Cell Separation
      • 8.3.2.3. Cell Analysis
      • 8.3.2.4. Molecular Analysis
      • 8.3.2.5. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Specialised Cancer Treatment Centers*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Merck KGaA*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Thermo Fisher Scientific, Inc.
  • 12.4. Bionomics.
  • 12.5. AbbVie, Inc.
  • 12.6. Stemline Therapeutics, Inc
  • 12.7. LONZA
  • 12.8. PromoCell GmbH
  • 12.9. Miltenyi Biotec
  • 12.10. STEMCELL Technologies Inc
  • 12.11. BIOTIME, Inc

LIST NOT EXHAUSTIVE

13. Global Cancer Stem Cells Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us